Estrogen receptor-β expression in extraabdominal fibromatoses: An analysis of 40 cases

Cancer

Volumn 106, Issue 1, 2006, Pages 208-213

  Deyrup, Andrea T ^a   Tretiakova, Maria ^b   Montag, Anthony G ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Desmoid; Estrogen receptor (ER); Estrogen receptor ; Fibromatosis; Immunohistochemical; Radioligand

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR BETA; RADIOLIGAND;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DESMOID TUMOR; FEMALE; FIBROBLAST; FIBROMATOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MALE; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; RECURRENCE RISK; TISSUE DISTRIBUTION; TUMOR GROWTH;

ABDOMEN; ADOLESCENT; ADULT; AGED; CHILD; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FIBROMATOSIS, AGGRESSIVE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RADIOLIGAND ASSAY; TUMOR MARKERS, BIOLOGICAL;

EID: 29744446453     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21553     Document Type: Article

References (37)

1. Hayry P, Reitamo JJ, Vihko R, et al. The desmoid tumor. III. A biochemical and genetic analysis. Am J Clin Pathol. 1982;77:681-685.
2. Hayry P, Reitamo JJ, Totterman S, Hopfner-Hallikainen D, Sivula A. The desmoid tumor. II. Analysis of factors possibly contributing to the etiology and growth behavior. Am J Clin Pathol 1982;77:674-680.
3. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996;392:49-53.
4. Taylor AH, Al-Azzawi F. Immunolocalization of oestrogen receptor beta in human tissues. J Mol Endocrinol. 2000;24:145-155.
5. Fletcher CDM, Unni KK, Mertens F, editors. Desmoid-type fibromatoses in World Health Organization Classification of Tumours: pathology and genetics tumours of soft tissue and bone. Lyon, France: IARC Press, 2002.
6. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2003;100:612-620.
7. Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. Br J Surg. 1996;83:1494-1504.
8. Weiss SW, Langloss JM, Shmookler BM, et al. Estrogen receptor protein in bone and soft tissue tumors. Lab Invest. 1986;54:689-694.
9. Lim CL, Walker MJ, Mehta RR, Das Gupta TK. Estrogen and antiestrogen binding sites in desmoid tumors. Eur J Cancer Clin Oncol 1986;22:583-587.
10. Maddalozzo J, Tenta LT, Hutchinson LR, Crawford SE, Morse DS. Juvenile fibromatosis: hormonal receptors. Int J Pediatr Otorhinolaryngol. 1993;25:191-199.
11. Rasbridge SA, Gillett CE, Millis RR. Oestrogen and progesterone receptor expression in mammary fibromatosis. J Clin Pathol. 1993;46:349-351.
12. Devouassoux-Shisheboran M, Schammel MD, Man YG, Tavassoli FA. Fibromatosis of the breast: age-correlated morphofunctional features of 33 cases. Arch Pathol Lab Med. 2000;124:276-280.
13. Sorensen A, Keller J, Nielsen OS, Jensen OM. Treatment of aggressive fibromatosis: a retrospective study of 72 patients followed for 1-27 years. Acta Orthop Scand. 2002;73:213-219.
14. Picariello L, Tonelli F, Brandi ML. Selective oestrogen receptor modulators in desmoid tumours. Expert Opin Investig Drugs. 2004;13:1457-1468.
15. Serpell JW, Paddle-Ledinek JE, Johnson WR. Modification of desmoid tumours in tissue culture by anti-oestrogenic substances: a preliminary report. Aust N Z J Surg. 1996;66:457-463.
16. King WJ, DeSombre ER, Jensen EV, Greene GL. Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors. Cancer Res. 1985;45:293-304.
17. Moffatt EJ, Kerns BJ, Madden JM, Layfield LJ. Prognostic factors for fibromatoses: a correlation of proliferation index, estrogen receptor, p53, retinoblastoma, and src gene products and clinical features with outcome. J Surg Oncol. 1997;65:117-122.
18. Brouillet JP, Dujardin MA, Chalbos D, et al. Analysis of the potential contribution of estrogen receptor (ER) beta in ER cytosolic assay of breast cancer. Int J Cancer. 2001;95:205-208.
19. Brooks MD, Ebbs SR, Colletta AA, Baum M. Desmoid tumours treated with triphenylethylenes. Eur J Cancer. 1992;28A:1014-1018.
20. Tonelli F, Ficari F, Valanzano R, Brandi ML. Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. Tumori. 2003;89:391-396.
21. Klemi P, Alanen K, Hietanen S, Grenman S, Varpula M, Salmi T. Response of estrogen receptor-positive intraabdominal fibromatosis to aromatase inhibitor therapy. Obstet Gynecol. 2003;102:1155-1158.
22. Wilcken N, Tattersall MHN. Endocrine therapy for desmoid tumors. Cancer. 1991;68:1384-1388.
23. Bauernhofer T, Stoger H, Schmid M, et al. Sequential treatment of recurrent mesenteric desmoid tumors. Cancer. 1996;77:1061-1065.
24. Lanari A. Effect of progesterone on desmoid tumours (aggressive fibromatosis). N Engl J Med. 1983;309:1523.
25. Waddell WR, Gerner RE. Indomethacin and ascorbate inhibit desmoid tumors. J Surg Oncol. 1980;15:85-90.
26. Tsukada K, Church JM, Jagelman DG, et al. Noncytotoxic drug therapy for intra-abdominal desmoid tumour in patients with familial adenomatous polyposis. Dis Colon Rectum. 1992;35:29-33.
27. Waddell WR, Kirsch WM. Testolactone, sulindac, warfarin, and vitamin K1 for unresectable desmoid tumors. Am J Surg. 1991;20:453-457.
28. Lazier CB, Bapat BV. Antiestrogen binding sites: general and comparative properties. J Steroid Biochem. 1988;31:665-669.
29. de Medina P, Favre G, Poirot M. Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. Curr Med Chem Anti-Canc Agents. 2004;4:491-508.
30. Jones JA, Albright KD, Christen RD, Howell SB, McClay EF. Synergy between Tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites. Cancer Res. 1997;57:2657-2660.
31. Locci PL, Bellocchio S, Lilli C, et al. Synthesis and secretion of transforming growth factor betal by human desmoid fibroblast cell line and its modulation by toremifene. J Interferon Cytokine Res. 2001;21:961-970.
32. Giarola M, Wells D, Mondini P, et al. Mutations of adenomatous polyposis coli (APC) gene are uncommon in sporadic desmoid tumors. Br J Cancer. 1998;78:582-587.
33. Tejpar S, Nollett F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogens, 1999;18:6615-6620.
34. Montgomery E, Lee JH, Abraham SC, Wu TT. Superficial fibromatoses are genetically distinct for deep fibromatoses. Mod Pathol. 2001;14:695-701.
35. Scholten AN, Creutzberg CL, vanden Broek LJ, Noordijk EM, Smit VT. Nuclear beta-catenin is a molecular feature of type I endometrial carcinoma. J Pathol. 2003;201:460-465.
36. Nakatani Y, Masudo K, Nozawa A, et al. Biotin-rich, optically clear nuclei express estrogen receptor-beta: tumors with morules may develop under the influence of estrogen and aberrant beta-catenin expression. Hum Pathol. 2004;35:869-874.
37. Kouzmenko AP, Takeyama K, Ito S, et al. Wnt/beta catenin and estrogen signaling converge in vivo. J Biol Chem. 2004;279:40255-40258.